Nationwide, outbreak.info estimates that BA.2.86’s cumulative prevalence — which represents a ratio of sequences containing BA.2.86 to all sequences collected in the U.S. since the subvariant was first detected on July 29 — is less than 0.5 percent.
The subvariant made headlines in August because of its large number of mutations, however emerging research suggests the strain may not be as transmissible or immune-evasive as experts initially thought.
Below is a breakdown of BA.2.86 prevalence by state, based on data from outbreak.info. As COVID-19 sequencing is not a random sample of mutations, the data represents outbreak.info’s best estimates of the subvariant’s prevalence, as opposed to true prevalence.
Note: Becker’s calculated each state’s estimated cumulative BA.2 presence using sequencing data from outbreak.info. Figures are rounded to the nearest hundredth.
|
State |
BA.2.86 positive samples |
Total sequences sampled |
Estimated cumulative prevalence (%) |
|
Pennsylvania |
1 |
166 |
.60 |
|
Michigan |
1 |
230 |
.43 |
|
Ohio |
1 |
297 |
.34 |
|
Washington |
1 |
532 |
.19 |
|
Virginia |
1 |
541 |
.18 |
|
Colorado |
1 |
750 |
.13 |
|
Texas |
1 |
2,815 |
.04 |
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
